This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

NGM Biopharmaceuticals (NGM) Hisse Özeti

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. Daha fazla detay

NGM temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Gelirin yılda 57.57% oranında artması öngörülüyor

Risk Analizi

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Anlamlı bir geliri yok ( $4M )

NGM Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

NGM Biopharmaceuticals, Inc. Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti NGM Biopharmaceuticals
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$1.54
52 Haftanın En Yüksek Seviyesi	US$4.69
52 Haftanın En Düşük Seviyesi	US$0.60
Beta	1.27
1 Aylık Değişim	1.32%
3 Aylık Değişim	14.93%
1 Yıllık Değişim	-59.79%
3 Yıllık Değişim	-93.94%
5 Yıllık Değişim	-90.41%
Halka arzdan bu yana değişim	-89.52%

Son Haberler & Güncellemeler

Recent updates

Analiz Makalesi • Dec 19

What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You

NGM Biopharmaceuticals, Inc. ( NASDAQ:NGM ) shareholders are no doubt pleased to see that the share price has bounced...

Analiz Makalesi • Oct 05

We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Analiz Makalesi • Aug 09

Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates

Today is shaping up negative for NGM Biopharmaceuticals, Inc. ( NASDAQ:NGM ) shareholders, with the analysts delivering...

Analiz Makalesi • Jun 27

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analiz Makalesi • Apr 17

NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't

NGM Biopharmaceuticals, Inc.'s ( NASDAQ:NGM ) price-to-sales (or "P/S") ratio of 5.3x might make it look like a strong...

Analiz Makalesi • Dec 20

We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Seeking Alpha • Oct 17

NGM Biopharma sinks ~72% after phase 2 trial of its eye degeneration treatment fails

NGM Biopharmaceuticals (NASDAQ:NGM) on Monday said its phase 2 trial of its monoclonal antibody NGM621 for the treatment of eye disease geographic atrophy failed to meet its main goal. Shares of the small-cap biotech plunged 72.2% to $3.21 in premarket trading. The mid-stage trial, called CATALINA, was evaluating NGM621 for patients with geographic atrophy (GA), which is the progressive degeneration of the macula in the eye and is an advanced form of age-related macular degeneration. NGM said the trial did not meet the primary endpoint of statistically significant rate of change in GA lesion area using slope analysis over 52 weeks for NGM621 versus sham. However, the company said the treatment showed favorable safety and tolerability. The company plans to present further analyses in early Nov. at a conference.

Seeking Alpha • Jun 30

NGM Biopharmaceuticals appoints CFO Siobhan Nolan Mangini to the additional role of President

Siobhan Nolan Mangini, CFO of NGM Biopharmaceuticals (NASDAQ:NGM) has been appointed to the additional role of President. David J. Woodhouse, Ph.D. will continue to serve as NGM Bio’s Chief Executive Officer. William J. Rieflin, who has served as Executive Chairman of company’s Board since September 2018, will transition to Chairman of the Board effective July 1, 2022.

Seeking Alpha • Jun 21

NGM Biopharmaceuticals: Eye Disorder Data Due Second Half Of 2022

Results from the phase 2 CATALINA study using NGM621 for the treatment of patients with Geographic Atrophy are expected in the 2nd half of 2022. Results from a phase 1/2 study using NGM707 for the treatment of patients with advanced cancer are expected in the 2nd half of 2022. Results from the phase 2b ALPINE4 study using aldafermin for the treatment of patients with compensated NASH cirrhosis are expected 1st half of 2023. NGM Biopharmaceuticals had $329.8 million in cash as of March 31, 2022. It believes it has enough cash to fund its operations for at least the next 12 months.

Analiz Makalesi • Jun 15

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analiz Makalesi • May 09

Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week

Celebrations may be in order for NGM Biopharmaceuticals, Inc. ( NASDAQ:NGM ) shareholders, with the analysts delivering...

Seeking Alpha • Apr 26

NGM Biopharmaceuticals: How They Changed A Dead End To A Crossroad

After last year's NASH flop, NGM was written off as a lost cause. The company has been able to turn itself around. Today it is an oncology-focused company with multiple interesting assets.

Analiz Makalesi • Feb 21

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analiz Makalesi • Nov 08

We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Analiz Makalesi • Jul 09

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Analiz Makalesi • Mar 06

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Last week, you might have seen that NGM Biopharmaceuticals, Inc. ( NASDAQ:NGM ) released its full-year result to the...

Hissedar Getirileri

	NGM	US Pharmaceuticals	US Pazar
7D	-3.1%	4.5%	-4.1%
1Y	-59.8%	37.3%	20.6%

Getiri vs. Endüstri: NGM geçen yıl % 37.3 oranında getiri sağlayan US Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: NGM geçen yıl % 20.6 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is NGM's price volatile compared to industry and market?
NGM volatility
NGM Average Weekly Movement	10.3%
Pharmaceuticals Industry Average Movement	9.8%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: NGM hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.

Zaman İçindeki Volatilite: NGM 'nin haftalık oynaklığı ( 10% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2007	138	David Woodhouse	www.ngmbio.com

NGM Biopharmaceuticals, Inc. Temel Bilgiler Özeti

NGM Biopharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
NGM temel i̇stati̇sti̇kler
Piyasa değeri	US$128.53m
Kazançlar(TTM)	-US$142.37m
Gelir(TTM)	US$4.42m

29.1x

P/S Oranı

-0.9x

F/K Oranı

NGM aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
NGM gelir tablosu (TTM)
Gelir	US$4.42m
Gelir Maliyeti	US$114.23m
Brüt Kâr	-US$109.81m
Diğer Giderler	US$32.56m
Kazançlar	-US$142.37m

Son Raporlanan Kazançlar

Dec 31, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.71
Brüt Marj	-2,486.12%
Net Kâr Marjı	-3,223.34%
Borç/Özkaynak Oranı	0%

NGM uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/04/05 22:32
Gün Sonu Hisse Fiyatı	2024/04/05 00:00
Kazançlar	2023/12/31
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

NGM Biopharmaceuticals, Inc. 7 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Matthew Luchini	BMO Capital Markets Equity Research
Mayank Mamtani	B. Riley Securities, Inc.
Paul Choi	Goldman Sachs

This company has been acquired

NGM Biopharmaceuticals (NGM) Hisse Özeti

Ödüller

Risk Analizi

NGM Biopharmaceuticals, Inc. Rakipler

Clearside Biomedical

MediWound

Sofgen Pharma

Nektar Therapeutics

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

NGM Biopharmaceuticals, Inc. announced that it has received $122 million in funding from The Column Group, LLC and other investors

NGM Biopharmaceuticals Files Form 15

The Column Group, LLC completed the acquisition of 74% stake in NGM Biopharmaceuticals, Inc. (NasdaqGS:NGM) from other group of shareholders.

The Column Group, LLC entered into a definitive Agreement to acquire 74% stake in NGM Biopharmaceuticals, Inc. (NasdaqGS:NGM) from other group of shareholders for approximately $130 million.

NGM Biopharmaceuticals to Become Privately Held Company and its Shares to be No Longer Listed on Nasdaq as Result of Closing of the Tender Offer

NGM Bio Announces New Clinical Data from Ongoing Trial of Ngm707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and Ngm120 to Focus on Rare Conditions with Significant Unmet Need

Recent updates

NGM Biopharmaceuticals, Inc. announced that it has received $122 million in funding from The Column Group, LLC and other investors

NGM Biopharmaceuticals Files Form 15

The Column Group, LLC completed the acquisition of 74% stake in NGM Biopharmaceuticals, Inc. (NasdaqGS:NGM) from other group of shareholders.

The Column Group, LLC entered into a definitive Agreement to acquire 74% stake in NGM Biopharmaceuticals, Inc. (NasdaqGS:NGM) from other group of shareholders for approximately $130 million.

NGM Biopharmaceuticals to Become Privately Held Company and its Shares to be No Longer Listed on Nasdaq as Result of Closing of the Tender Offer

NGM Bio Announces New Clinical Data from Ongoing Trial of Ngm707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and Ngm120 to Focus on Rare Conditions with Significant Unmet Need

What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You

NGM Biopharmaceuticals Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

NGM Biopharmaceuticals, Inc. Presents Positive Phase 2b Results from the Alpha 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting

Consensus revenue estimates decrease by 41%, EPS upgraded

Price target decreased by 19% to US$4.83

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Ngm Biopharmaceuticals, Inc. Appoints Irene Perlich as Principal Accounting Officer, Effective September 15, 2023

NGM Biopharmaceuticals, Inc. Announces Appointment of Irene Perlich as Principal Accounting Officer, Effective September 15, 2023

Consensus revenue estimates fall by 26%

Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates

Second quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Insufficient new directors

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky

Consensus revenue estimates decrease by 47%, EPS upgraded

First quarter 2023 earnings: EPS and revenues miss analyst expectations

NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't

Consensus EPS estimates fall by 23%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Founder exercised options and sold US$316k worth of stock

We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully

NGM Biopharmaceuticals, Inc. Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual Meeting

Price target increased to US$6.20

NGM Bio Announces Poster Presentation Featuring Initial Findings from Ph1a Trial of NGM707 in Patients with Advanced Solid Tumors at Upcoming 2022 ESMO-IO Annual Meeting

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Ngm Biopharmaceuticals, Inc. Announces Presentation of Post-Hoc Analyses from Catalina Phase 2 Trial of Ngm621 in Patients with Geographic Atrophy (Ga) Secondary to Age-Related Macular Degeneration At the Retina Society Annual Scientific Meeting

Lead Independent Director recently bought US$462k worth of stock

Ngm Biopharmaceuticals, Inc. (Ngm Bio) Announces Topline Efficacy and Safety Results from Its Randomized, Double-Masked, Sham-Controlled Catalina Phase 2 Trial of Ngm621 in Patients with Geographic Atrophy (Ga) Secondary to Age-Related Macular Degeneration

Price target decreased to US$28.75

NGM Biopharma sinks ~72% after phase 2 trial of its eye degeneration treatment fails

Consensus revenue estimates fall by 11%

Consensus revenue estimates fall by 22%

Second quarter 2022 earnings released: US$0.59 loss per share (vs US$0.48 loss in 2Q 2021)

Price target decreased to US$32.50

NGM Biopharmaceuticals, Inc. Announces Executive Changes

NGM Biopharmaceuticals appoints CFO Siobhan Nolan Mangini to the additional role of President

NGM Biopharmaceuticals: Eye Disorder Data Due Second Half Of 2022

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

NGM Biopharmaceuticals, Inc. Announces Initiation of Phase 1/1B Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors

Consensus forecasts updated

Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

NGM Biopharmaceuticals: How They Changed A Dead End To A Crossroad

NGM Biopharmaceuticals, Inc. to Present Late-Breaking Preclinical Research at 2022 AACR Annual Meeting Supporting Development of its Myeloid Reprogramming Portfolio

NGM Biopharmaceuticals, Inc., Annual General Meeting, May 18, 2022

NGM Biopharmaceuticals, Inc. Announces It Has Dosed the First Patient in A Phase 1/1B Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

CEO & Director exercised options to buy US$313k worth of stock.

Founder notifies of intention to sell stock

Founder notifies of intention to sell stock

We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely

Third quarter 2021 earnings released: US$0.37 loss per share (vs US$0.43 loss in 3Q 2020)

High number of new directors

Founder notifies of intention to sell stock

Founder notifies of intention to sell stock